系统医学2019年9月第4卷第17期DOI:10.19368/j.cnki.2096-1782.2019.17.147窑肿瘤学研究窑多西紫杉醇联合卡培他滨治疗晚期乳腺癌的临床分析石贤清江苏省人民医院溧阳分院肿瘤内科袁江苏溧阳213300[摘要]目的分析晚期乳腺癌患者采用多西紫杉醇尧卡培他滨联合用药治疗的效果遥方法该次研究针对目标为对照组单纯以多西紫杉醇药物治疗袁观察组以多西紫杉醇尧卡培他滨药物联合治疗袁对比总疗效袁检测并分析患者治疗前后肿瘤标志物及细胞因子指标差异袁统计并计算不良反应发生率遥结果观察组总疗效68.57%明显优于对照组28.57%袁差异有统计学意义渊字2=8.49袁P约0.05冤袁同时治疗后CEA渊6.35依1.02冤滋g/mL尧CA125渊38.25依2.14冤对照组袁差异有统计学意义渊t=15.17尧29.13尧41.59尧17.70尧66.95尧94.69袁P约0.05冤遥观察组患者出现不良反应的概率渊11.43%冤更小袁差异有统计学意义渊字2=10.08袁P约0.05冤遥结论晚期乳腺癌患者采取联合多西紫杉醇尧卡培他滨药U/mL尧CA15-3(30.98依1.04)U/mL尧P53渊6.26依1.14冤ng/mL尧VEGF渊68.48依2.06冤ng/mL尧MMP-9渊32.79依1.04冤mg/L均低于2016年9月要2018年9月该院肿瘤科收治70例乳腺癌患者袁参照计算机抽选结果将其分为观察组与对照组袁物治疗效果更佳袁能够进一步降低肿瘤标志物及细胞因子指标袁不良反应少袁值得推广遥[关键词]多西紫杉醇曰卡培他滨曰晚期曰乳腺癌曰临床分析[中图分类号]R737[文献标识码]A[文章编号]2096-1782渊圆园员9冤09渊a冤原园147-03ClinicalAnalysisofDocetaxelCombinedwithCapecitabineintheTreat鄄mentofAdvancedBreastCancerSHIXian-qingDepartmentofOncology,LiyangBranch,JiangsuProvincialPeople'sHospital,Liyang,JiangsuProvince,213300China[Abstract]ObjectiveToanalyzetheeffectofcombinationtherapywithdocetaxelandcapecitabineinpatientswithad鄄vancedbreastcancer.MethodsTheaimofthisstudywastotreat70patientswithbreastcancerwhowereadmittedtoourdepartmentofoncologyfromSeptember2016toSeptember2018.Theresultsweredividedintoobservationgrouptheobservationgroupwastreatedwithdocetaxelandcapecitabine.Thetotaleffectwascompared.Thedifferencesoftumormarkersandcytokineindexesbeforeandaftertreatmentweredetectedandanalyzed.Theincidenceofadverseandcontrolgroupaccordingtotheresultsofcomputersampling.Thecontrolgroupwastreatedwithdocetaxelalone,reactionswascalculatedandcalculated.ResultsThetotalefficacyoftheobservationgroupwas68.57%,whichwasAtthesametime,CEA(6.35依1.02)滋g/mL,CA125(38.25依2.14)U/mL,CA15-3(30.98依1.04)U/mL,P53(6.26依1.14)ng/mL,VEGF(68.48依2.06)ng/mL,andMMP-9(32.79依1.04)mg/Lwerelowerthanthecontrolgroup袁thedifferencewassta鄄tisticallysignificant(t=15.17,29.13,41.59,17.70,66.95,94.69,P约0.05).Theprobabilityofadversereactionsintheob鄄servationgroupwassmaller渊11.43%冤袁thedifferencewasstatisticallysignificant(字2=10.08,P约0.05).ConclusionPa鄄significantlybetterthanthatofthecontrolgroup28.57%袁thedifferencewasstatisticallysignificant(字2=8.49,P约0.05).tientswithadvancedbreastcancerarebettertreatedwithdocetaxelandcapecitabine,whichcanfurtherreducetumormarkersandcytokineindexes,withfeweradversereactionsandworthpromoting.[Keywords]Docetaxel;Capecitabine;Advanced;Breastcancer;Clinicalanalysis乳腺癌是临床较为常见的恶性肿瘤疾病之一袁指的是乳腺上皮细胞出现癌变袁大量增殖的细胞损害乳[作者简介]石贤清渊1984-冤袁女袁安徽马鞍山人袁本科袁主治医师袁研究方向院胃肠道肿瘤及乳腺肿瘤遥房结构袁进而使患者出现乳房疼痛尧乳头溢乳尧乳腺结块等症状表现[1-2]遥当前袁该疾病的常用药物大致为紫杉醇类化药及蒽环类化药袁尽管效果良好袁然而患者易发生复发尧转移尧耐药等情况袁且不良反应相对较SYSTEMSMEDICINE系统医学147
多西紫杉醇联合卡培他滨治疗晚期乳腺癌的临床分析 - 论文
